Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 941 to 950 of 974 total matches.
Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019 (Issue 1564)
before use of the drug in patients with
phenylketonuria.
PREGNANCY — There are no adequate data ...
The FDA has approved Plenvu (Salix), a polyethylene
glycol (PEG)-containing oral powder for reconstitution,
for colon cleansing prior to colonoscopy in adults.
Plenvu is the first PEG-containing colonoscopy preparation
that requires only 1 L of water for dissolution and
ingestion of 1 L of clear fluid in addition.
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
they reduce the ef ficacy of the drug
is unknown.
PREGNANCY — Administration of romosozumab to
pregnant ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
in approximately 1%
of patients.
PREGNANCY AND LACTATION — Human IgG antibodies
cross the placenta (especially ...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
is recommended
when amisulpride is used with other drugs that also
prolong the QT interval.8
PREGNANCY ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
with a quadrivalent
inactivated influenza vaccine.
PREGNANCY AND LACTATION — There are no
data on the use of PCV20 ...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years...
Treatment of Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
of pregnancy
prevention.
10,11
Progestins alone are somewhat effective for treatment of hot flashes in women ...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Arformoterol (Brovana) for COPD
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
in pregnancy (teratogenic in animals). The labels of long-acting beta
2
-agonists warn that their use ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Vigabatrin (Sabril) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010 (Issue 1332)
be
ruled out) for use in pregnancy.
DRUG INTERACTIONS — Vigabatrin can lower
serum concentrations ...
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Saxagliptin (Onglyza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
in humans) for use
during pregnancy.
DRUG INTERACTIONS — Saxagliptin is metabolized to an active ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
with
moderate or severe hepatic impairment.
PREGNANCY — Use of elbasvir/grazoprevir in
pregnant women ...
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection.